ALYREF and neoplasm: Finally, in a cisplatin-resistant subcutaneous tumor mouse model (Fig. 7H), ALYREF knockdown significantly reduced cisplatin resistance and led to downregulation of ALYREF, LGR4, and β-Catenin protein levels in tumor tissues (Figs. 7I and S9B, C).